Dr. Reddy's Laboratories share news, announcements and annual reports
NSE: DRREDDYBSE: 500124Pharmaceuticals & BiotechnologyMid Cap
Dr. Reddy's Laboratories Limited · Face value ₹1 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Aug 1986 on BSE, May 2003 on NSE
Last close ₹1,342.00down ₹10.00 (0.74%)BSE ₹1,340.25
Share price at the NSE close on 2 Nov 2026. Previous close ₹1,352.00.
2 Nov: open ₹1,352.00, high ₹1,364.90, low ₹1,336.70
52-week range of traded prices to 2 Nov 2026
₹1,101.00Low, 23 Jul 2026₹1,414.90High, 29 Jun 2026
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹1,12,014 Cr104th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 40.01
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 2.89
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.60%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 7.5%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 6.0%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Sep 2026.
- 0.15
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 20,54,11666.5% delivered
Dr. Reddy's Laboratories share news and announcements
1,702 announcements, routine notices left out, newest first. Page 26 of 35.
Jan 2015
9 Jan · Legal
Exchange has sought clarification from Dr. Reddy's Laboratories Limited with respect to news item captioned "Maharashtra suspends Dr Reddy's licenses". In this regard, Exchange have advised the Company to provide clarification/confirmation on the news item in detail including the following: a) Whether such event/negotiations/article stated in published news were taking place? If so, you are advised to provide the said information along with the sequence of events in chronological order and the material impact of this article on the Company. b) Whether company are aware of any information that has not been announced to the Exchanges under clause 36 of the Listing Agreement. The response from the Company is awaited.6 Jan · Board meeting
Inter alia, to consider and approve the Unaudited Financial Results of the Company for the quarter and nine months ended December 31, 2014.
Dec 2014
26 Dec · Legal
Exchange had sought clarification from Dr. Reddy's Laboratories Limited with respect to a news item captioned "Indian pharma now under Canada lens . The Company has clarified that : In keeping with current regulations of Health Canada, the Company has voluntarily placed under quarantine all APIs and the formulations based on APIs produced at our API facility in Srikakulam district of Andhra Pradesh intended for use in Canada. Our products continue to meet intended quality standards, and we believe that, our APIs and Finished drug products manufactured using these APIs pose no risk to the health and safety of the Canadian people. The Company is working with the agency for a satisfactory resolution of the matter. At this stage, it has no implication on any activity at the plant and hence, these are not expected to be material to the Company s operations or consolidated results.26 Dec · Legal
Exchange has sought clarification from Dr. Reddy's Laboratories Limited with respect to news item captioned "Indian pharma now under Canada lens". In this regard, Exchange have advised the Company to provide clarification/confirmation on the news item in detail including the following: a) Whether such event/negotiations/article stated in published news were taking place? If so, you are advised to provide the said information along with the sequence of events in chronological order and the material impact of this article on the Company. b) Whether company are aware of any information that has not been announced to the Exchanges under clause 36 of the Listing Agreement. The response from the Company is awaited.11 Dec · Legal
Exchange had sought clarification from Dr. Reddy's Laboratories Limited with respect to a news item captioned "Germany bans 80 generic drugs for insufficient trials". The Company has clarified that "Dr. Reddy s through its local entity Betapharm is proceeding in line with the instructions of the regulator. Overall impact on the financials of this action is expected to be non-material".11 Dec · Legal
Exchange has sought clarification from Dr. Reddy's Laboratories Limited with respect to news item captioned "Germany bans 80 generic drugs for insufficient trials". In this regard, Exchange have advised the Company to provide clarification/confirmation on the news item in detail including the following: a) Whether such event/negotiations/article stated in published news were taking place? If so, you are advised to provide the said information along with the sequence of events in chronological order and the material impact of this article on the Company. b) Whether company are aware of any information that has not been announced to the Exchanges under clause 36 of the Listing Agreement. The response from the Company is awaited.
Nov 2014
27 Nov · Legal
Exchange has sought clarification from Dr. Reddy's Laboratories Limited with respect to news item dated November 27, 2014, captioned "Srikakulam plant gets Form 483 for lapses: DRL". In this regard Company has clarified as under: a) Whether such event/negotiations/article stated in published news were taking place? If so, you are advised to provide the said information along with the sequence of events in chronological order and the material impact of this article on the Company. The Company has received some inspectional observations from the US FDA after their visit to our API manufacturing facility in Srikakulam district of Andhra Pradesh. The Company is committed to respond to the agency within stipulated timelines with our remedial plans and start implementing the necessary measures immediately. At this stage, it has no implication on any activity at the plant. Hence, these are not expected to be material to the Company's operations or consolidated results. b) Whether company are aware of any information that has not been announced to the Exchanges under clause 36 of the Listing Agreement. If so, you are advised to provide the said information and the reasons for not disclosing the same to the Exchange earlier as required under clause 36 of the Listing Agreement. For reasons stated in response to question (a) above, we did not see a stock exchange notification necessary.27 Nov · Legal
Exchange has sought clarification from Dr. Reddy's Laboratories Limited with respect to recent news item captioned "Srikakulam plant gets Form 483 for lapses: DRL". In this regard, Exchange have advised the Company to provide clarification/confirmation on the news item in detail including the following: a) Whether such event/negotiations/article stated in published news were taking place? If so, you are advised to provide the said information along with the sequence of events in chronological order and the material impact of this article on the Company. b) Whether company are aware of any information that has not been announced to the Exchanges under clause 36 of the Listing Agreement. The response from the Company is awaited.
Oct 2014
9 Oct · Legal
Exchange had sought clarification from Dr. Reddy's Laboratories Limited with respect to a news item captioned "Sun, Dr Reddy's, cadila named in US Congress price probe". The Company has clarified that "On October 2, 2014, Dr. Reddy s Laboratories Ltd. received notice from US Congress Committees on price escalation of its generic products of Divalproex Sodium ER and Pravastatin Sodium. The Company has strict internal policies of complying with all applicable statutes and regulatory requirements of markets in which it operates, globally. The Company is of the opinion that it has complied with all applicable product pricing norms. Also, Company's Divalproex Sodium ER marketing approval was received well after all market price increases were put in place by competitors. Company does not now market Pravastatin Sodium. Company is responding to the US Congress letter well within time. As it stands today, Company does not see the notice material to its operations or consolidated results".
Sep 2014
Aug 2014
1 Aug · Disclosure of Voting Pattern - Clause 35A
Jul 2014
7 Jul · Board meeting
Inter alia, to consider and approve the Unaudited Financial Results of the Company for the quarter ended June 30. 2014.
Jun 2014
May 2014
13 May · Results
Dr. Reddy's Laboratories Limited has informed the Exchange regarding the standalone Results for the quarter ended on 31-MAR-2014 as follows: Net Sales of Rs. 253227 lacs for the quarter ending on 31-MAR-2014 against Rs. 216090 lacs for the quarter ending on 31-MAR-2013. Net Profit / (Loss) of of Rs. 47143 lacs for the quarter ending on 31-MAR-2014 against Rs. 37815 lacs for the quarter ending on 31-MAR-2013.13 May · Results
Dr. Reddy's Laboratories Limited has informed the Exchange regarding the standalone Results for the year ended on 31-MAR-2014 as follows: Net Sales of Rs. 949572 lacs for year ending on 31-MAR-2014 against Rs. 807434 lacs for the year ending on 31-MAR-2013. Net Profit / (Loss) of Rs. 193284 lacs for the year ending on 31-MAR-2014 against Rs. 126547 lacs for the year ending on 31-MAR-2013.